Long-term clinical experience with amplatzer ductal occluder II for closure of the persistent arterial duct in children

2014 ◽  
Vol 83 (7) ◽  
pp. 1102-1108 ◽  
Author(s):  
Sok-Leng Kang ◽  
Gareth Morgan ◽  
Jonathan Forsey ◽  
Andrew Tometzki ◽  
Robin Martin
2016 ◽  
Vol 21 (2) ◽  
pp. 8 ◽  
Author(s):  
M. P. B. Goonetilleke ◽  
A. U. Jayaratne ◽  
H. A. M. Inthisar ◽  
N. D. Vithanage ◽  
K. W. R. Wimalagunarathne ◽  
...  

2014 ◽  
Vol 43 (4) ◽  
pp. 201
Author(s):  
M P B Goonetilleke ◽  
U A Jayarathna ◽  
H A M Inthisar ◽  
N D Vithanage ◽  
D R Palangasinghe ◽  
...  

2009 ◽  
Vol 74 (4) ◽  
pp. 615-623 ◽  
Author(s):  
Jonathan Forsey ◽  
Damien Kenny ◽  
Gareth Morgan ◽  
Alison Hayes ◽  
Mark Turner ◽  
...  

2018 ◽  
Vol 3 (3) ◽  

Introduction: Too many patients with moderate to severe psoriasis do not receive adequate treatment. This means a vast undersupply in the treatment of patients with psoriasis. Only biologics fulfill the whole range of the treatment of psoriasis – psoriasis does not affect only skin but the whole organism: It is a systemic disease! Between the biologics are evident differences concerning the effect. Discussion: Based on broad personal experience in the management of patients with moderate to severe psoriasis new data from clinical studies with ixekizumab are examined. This contains new data on long-term-efficacy of ixekizumab, effectiveness in special localizations (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis) as well as safely data and experience on patients switched to ixekizumab from other biologics. Personal clinical experience is based on >300 non-selected outpatients with moderate to severe psoriasis, >250 patients on biological therapies, > 50 patients with ixekizumab. Conclusions: Focusing on a relevant number of patients switched from secukinumab to ixekizumab due to first or secondary loss of efficacy significant differences between both IL-17A-inhibitors mainly in terms of efficacy and speed of therapeutic response are shown. Finally the correlation between PASI-90-/PASI-100 response and significant changes in DLQI are highlighted.


2002 ◽  
Vol 13 (9) ◽  
pp. 909-914 ◽  
Author(s):  
Kwang-Hun Lee ◽  
Gi-Young Ko ◽  
Ho-Young Song ◽  
Tae Sun Shim ◽  
Woo Sung Kim

Heart ◽  
1994 ◽  
Vol 72 (4) ◽  
pp. 364-367 ◽  
Author(s):  
M A Gatzoulis ◽  
M L Rigby ◽  
A N Redington

2003 ◽  
Vol 29 (3) ◽  
pp. 164-173 ◽  
Author(s):  
Dirk Wildemeersch ◽  
Istvan Batar ◽  
Biran Affandi ◽  
Amaury Andrade ◽  
Wu Shangchun ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document